You are here

rebates

Biosimilar makers split strategies in bid to take on top-selling Humira

Biosimilar makers split strategies in bid to take on top-selling Humira

BioPharma Dive

Boehringer Ingelheim

Flag link:

Pfizer's Supreme Court challenge of US kickback law is 'far-fetched,' HHS says

Pfizer's Supreme Court challenge of US kickback law is 'far-fetched,' HHS says

Fierce Pharma

Flag link:

Recent Developments in the Medicaid Drug Rebate Program

Recent Developments in the Medicaid Drug Rebate Program

FDA Law Blog

Flag link:

CMS to delay part of controversial Medicaid drug rule

CMS to delay part of controversial Medicaid drug rule

Beckers Hospital Review

Flag link:

McKinsey consultants proposed Purdue offer rebates for opioid overdoses: NYT

McKinsey consultants proposed Purdue offer rebates for opioid overdoses: NYT

Fierce Pharma

Flag link:

Mallinckrodt could owe a whopping $650M in Acthar Medicaid rebates

Mallinckrodt could owe a whopping $650M in Acthar Medicaid rebates

Fierce Pharma

specialty generics

H.P. Acthar Gel

Flag link:

More than half of its gross sales ultimately went to payers as rebates, Sanofi says

More than half of its gross sales ultimately went to payers as rebates, Sanofi says

Endpoints

Flag link:

Drugmakers could avoid paying rebates under new FDA guidance

Drugmakers could avoid paying rebates under new FDA guidance

Beckers Hospital Review

Flag link:

Employers Slowly Warm to Point-of-Sale Rebates—But Must Move Faster for Insulin

Employers Slowly Warm to Point-of-Sale Rebates—But Must Move Faster for Insulin

Drug Channels

point-of-sale rebates

Flag link:

Massachusetts compromises on weaker Medicaid drug price disclosure

Massachusetts compromises on weaker Medicaid drug price disclosure

BioCentury

Flag link:

PBMs send another ad message to DC lawmakers, this time on drug price negotiations

PBMs send another ad message to DC lawmakers, this time on drug price negotiations

Fierce Pharma

Flag link:

Sanofi handed payers nearly $12B in drug rebates last year

Sanofi handed payers nearly $12B in drug rebates last year

Biopharma Dive

Flag link:

Medicare PBM rebate ban could migrate to private sector

Medicare PBM rebate ban could migrate to private sector

BioCentury

Medicare Part D

Flag link:

Trump administration to scrap Part D rebates

Trump administration to scrap Part D rebates

BioCentury

Medicare Part D

Flag link:

Abolishing Drug Rebates May Push Consumer Drug Costs Higher

Abolishing Drug Rebates May Push Consumer Drug Costs Higher

Forbes

Flag link:

A System Without Rebates: The Drug Channels Negotiated Discounts Model

A System Without Rebates: The Drug Channels Negotiated Discounts Model

Drug Channels

Flag link:

Pfizer CEO predicts that controversial rebates are ‘going away’

Pfizer CEO predicts that controversial rebates are ‘going away’

Stat

Flag link:

US Maps Strategy to Reform Drug Pricing

US Maps Strategy to Reform Drug Pricing

Pharm Exec

Flag link:

Janssen’s New Transparency Report: A Peek Behind the Drug Pricing Curtain Raises Troubling Questions About Rebates

Janssen’s New Transparency Report: A Peek Behind the Drug Pricing Curtain Raises Troubling Questions About Rebates

Drug Channels

Flag link:

Get ready for a drop in branded drug spending this year, thanks to rebates and discounts: report

Get ready for a drop in branded drug spending this year, thanks to rebates and discounts: report

Fierce Pharma

Flag link:

Pages